Nouvelle publication : An anti-diabetic drug targets NEET (CISD) proteins through destabilization of their [2Fe-2S] clusters
ENYO Pharma est fière de partager une étude collaborative internationale explorant le potentiel anti-diabétique de la molécule dEF2905 (M1) issue de la plateforme de drug discovery d’ENYO Pharma.
L’étude menée par le Pr Rachel Nechushtai de l’Université hébraïque de Jérusalem démontre l’efficacité de M1 pour corriger l’homéostasie défectueuse de la glycémie dans un modèle de souris diabétique par la déstabilisation du cluster [2Fe-2S] des protéines mitochondriales NEET. Cette publication met également en lumière la plateforme de drug discovery d’ENYO Pharma inspirée des virus.
New publication : An anti-diabetic drug targets NEET (CISD) proteins through destabilization of their [2Fe-2S] clusters
ENYO is proud to share international collaborative study showing the anti-diabetic potential of the small molecule dEF2905 (M1) designed by ENYO Pharma’s drugdiscovery platform.
The study driven by Pr R. Nechushtai from the Hebrew University of Jerusalem demonstrates the efficacy of M1 in correcting defective blood glucose homeostasis in a diabetic mouse model through [2Fe-2S] cluster destabilization of mitochondrial NEET proteins. This publication also highlights the ENYO Pharma’s drug discovery platform inspired by viruses.
We are pleased to sponsor the Swiss NASH Foundation launched in 2019 by Pr Jean-François Dufour. Its mission is to raise awareness and increase the knowledge about NASH and fatty liver in general. Through funding innovative research projects on NASH diagnostics, treatment and patient management, the foundation is joining the fight against this epidemic disease.
ENYO Pharma is in the Top 50 of the EIC ScalingUp List, in the Health Track. We were selected out of a universe of 3,000+ deeptech startups, as funded so far by the European Innovation Council (EIC) or SME Instrument. This is a fantastic business support for the growth of the company during this pivotal year.
ENYO Pharma has been highlighted in the “Best of The Liver Meeting 2021” for the oral presentation describing Vonafexor’s key effects after 12 weeks of treatment on liver and kidney functions in NASH patients, given by the LIVIFY Principal Investigator Pr Stephen Harrison during the Late Breaking Session 1 Sunday, November the 14th.